No Data
No Data
Pyxis Oncology Files to Sell 10.46M Common Shares for Holders
Pyxis Oncology Completed The Sale Of Its Rights To Royalties From The Commercialization Of Beovu (Brolucizumab-dbll) And Another Asset To Novartis For $8M
Pyxis Oncology Completed The Sale Of Its Rights To Royalties From The Commercialization Of Beovu (Brolucizumab-dbll) And Another Asset To Novartis For $8M
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen's licensees discovered
Optimistic Buy Rating for Pyxis Oncology's PYX-201 Based on Strong Safety Profile and Promising Therapeutic Potential
Insiders Who Sold Pyxis Oncology Made The Right Call As Market Cap Slides By US$50m
By selling US$81k worth of Pyxis Oncology, Inc. (NASDAQ:PYXS) stock at an average sell price of US$2.23 over the last year, insiders seemed to have made the most of their holdings. The company's mark
Pyxis Oncology Price Target Maintained With a $7.00/Share by RBC Capital
Pyxis Oncology Price Target Maintained With a $7.00/Share by RBC Capital
No Data